Lyra Therapeutics (LYRA) Cash from Restructuring (2024 - 2025)
Quarterly Cash from Restructuring rose 140.75% to $207000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$1.1 million for FY2025, 124.87% down from the prior year.
Lyra Therapeutics' Cash from Restructuring history spans 2 years, with the latest figure at $207000.0 for Q4 2025.
- Cash from Restructuring came in at $207000.0 for Q4 2025, up from -$427000.0 in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $1.7 million in Q3 2024 to a low of -$553000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Lyra Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 207,000.00 |
| Sep 30, 2025 | -427,000.00 |
| Jun 30, 2025 | -553,000.00 |
| Mar 31, 2025 | -308,000.00 |
| Dec 31, 2024 | -508,000.00 |
| Sep 30, 2024 | 1.73 Mn |